在多发性硬化症中,ocrelizumab调节IL-2信号通路和相关 lncRNAs
Fatemeh Rangani1, Mohammad Ali Nahayati2, Majid Pahlevan Kakhki3
1Department of Clinical Neuroscience, Karolinska Institutet, and Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Department of Medical Biotechnology and Nanotechnology, Mashhad University of Medical sciences, Mashhad, Iran.
Journal of the neurological sciences
|December 13, 2025
概括
对多发性硬化症的ocrelizumab治疗调节了介质素-2 (IL-2) 途径和长非编码RNAs (lncRNAs),影响免疫调节. 这表明在MS治疗中涉及IL-2信号和lncRNAs的新疗法机制.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 奥克雷利祖马布是一种CD20+ B细胞消耗抗体,用于多发性硬化症 (MS).
- 它对免疫调节的精确分子作用,特别是介质蛋白-2 (IL-2) 信号轴,尚未完全理解.
- IL-2通路对于免疫耐受性至关重要.
研究的目的:
- 研究ocrelizumab对IL-2信号通路中的关键基因和相关的长非编码RNA (lncRNAs) 的影响.
- 分析这些分子变化在伊朗复发性复发性多发性硬化症患者的队列.
- 探索基因表达,临床参数和治疗状态之间的相关性.
主要方法:
- 周围血液单核细胞 (PBMC) 从未接受MS治疗的患者,接受Ocrelizumab治疗的MS患者和健康对照组中收集.
- 使用RT-PCR分析了IL-2通路组件和特定lncRNA的基因表达水平.
- 进行了相关性和ROC分析,以评估分子标记物与临床数据之间的关系.
主要成果:
- 奥克雷利祖马布治疗减少了IL2RA和FOXP3的表达,但没有影响IL2水平.
- 在接受治疗的多发性硬化患者中,lncRNAs FLICR和RP11-536 K7.5的表达正常化.
- IL2RA表达与FOXP3相关,与RP11-536 K7.5相反;较低的IL2RA和RP11-536 K7.5与较高的EDSS分数相关.
- 随着Ocrelizumab注射次数的增加,FOXP3表达的增加.
结论:
- 奥克雷利祖马布调节IL-2信号通路,并影响MS患者的lncRNA表达.
- 这些分子变化,包括FOXP3指示的增强调节性T细胞活性,是Ocrelizumab的潜在治疗作用.
- IL-2通路基因和特定的 lncRNAs 显示出作为MS治疗反应的生物标志物的潜力.
相关概念视频
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445
NF-κB-dependent Signaling Pathway
9.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.7K


